Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients

British Journal of Cancer

Volumn 76, Issue 12, 1997, Pages 1655-1660

  Formelli, F ^a   Cavadini, E ^a   Mascheroni, L ^a   Belli, F ^a   Cascinelli, N ^a  

^a Pediatric Oncology Unit   (Italy)

Author keywords

13 cis retinoic acid; Melanoma; Pharmacokinetics; Retinol

Indexed keywords

DRUG METABOLITE; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID; RETINOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030710553     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.613     Document Type: Article

References (19)

1. Berni R, Clerici M, Malpeli G, Cleris L and Formelli F (1993) Retinoids: in vitro interaction with retinol-binding protein and influence on plasma retinol. FASEB J 7: 1179-1184
2. Brazzell RK, Vane FM, Ehmann CW and Colburn WA (1983) Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 24: 695-702
3. Cascinelli N, Bufalino R, Morabilo A and Mackie R (1994) Results of adjuvant interferon study in WHO melanoma programme. Lancet 343: 913-914
4. Colburn WA, Gibson DM, Wiens RE and Hanigan JJ (1983) Food increases the bioavailability of isotretinoin. J Clin Pharmacol 23: 534-539
5. Collins MD, Tzimas G, Hummler H, Burgin H and Nau H (1994) Comparative teratology and transplacental pharmacokinetics of all-trans-retinoic acid, 13-cis-retinoic acid, and retinyl palmitate following daily administrations in rats. Toxicoll Appl Pharmacol 127: 132-144
6. Fierlbeck G, Schreiner T and Rassner G (1995) Combination of highly purified human leukocyte interferon α and 13-cis-retinoic acid for the treatment of metastatic melanoma. Cancer Immunol Immunother 40: 157-164
7. Formelli F, Carsana R, Costa A, Buranelli F, Campa T, Dossena G, Magni A and Pizzichetta M (1989) Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 49: 6149-6152
8. Goodman GE, Einspahr JG, Alberts DS, Davis TP, Leigh SA, Chen HSG and Meyskens FL (1982) Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. Cancer Res 42: 2087-2091
9. Hong WK and Itri LM (1994) Retinoids and human cancer. In The Retinoids: Biology, Chemistry and Medicine. Sporn MB, Roberts AB and Goodman DS (eds), pp. 597-630. Raven Press: New York
10. Khoo KC, Reik D and Colburn WA (1982) Pharmacokinetics of isotretinoin following a single oral dose. J Clin Pharmacol 22: 395-402
11. Lippman SM, Kavanagh JJ, Peredes-Espinoza M, Delgadillo-Madrueno F, Peredes-Casillas P, Hong WK, Holdener E and Krakoff IH (1992a) 13-cis-retinoic acid plus interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J. Natl Cancer Inst 84: 241-245
12. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU and Hong WK (1992b) 13-cis-retinoic acid plus interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84: 235-240
13. Lotan R, Dawson MI, Zou CC, Jong L, Lotan D and Zou CP (1995) Enhanced efficacy of combinations of retinoic acid-and retinoid X receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res 55: 232-236
14. Marth C, Widschwendler M and Daxenbichler G (1993) Mechanism of synergistic action of all-trans-or 9-cis-retinoic acid and interferons in breast cancer cells. J Steroid Biochem Mol Biol 47: 123-126
15. Sass JO, Masgrau E, Saurat J-H and Nau H (1995) Metabolism of oral 9-cis-retinoic acid in the human. Identification of 9-cis-retinoyl-β-glucuronide as urinary metabolites. Drug Metab Disp 23: 887-891
16. Schaber B, Mayer P, Schreiner T, Rassner G and Fierlbeck G (1994) Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines. Melanoma Res 4: 321-326
17. Sheridan E and Hancock BW (1992) Systemic treatment of melastatic malignant melanoma. In Diagnosis and Management of Melanoma in Clinical Practice. Kirkham N, Cotton DWK, Lallemand RC, White JE and Rosin RD (eds) pp 135-152. Springer: London
18. Triozzi PL, Walker MJ, Pellegrini AE and Dayton MA (1996) Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest 14: 293-298
19. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NKC and Reynolds CP (1995) Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13: 894-901